The reimbursement progress of the anticancer drug that received 50,000 consents in a national petition is gaining attention.

According to industry sources, the reimbursement review data for Enhertu, AstraZeneca and Daiichi Sankyo’s HER2-directed antibody-drug conjugate (ADC), has been supplemented and submitted to the authorities on the 14th.

No reimbursement standard had been set for Enhertu at the Cancer Disease Review Committee (CDRC) meeting that was held in March. At the time, there was no disagreement among experts about the clinical usefulness of Enhertu. In other words, the reason why a standard had not been set was considered to be because of its potential financial burden on